Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IMRN 
Immuron Ltd ADR (IMRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: IMRN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.83
1 Year Target Price $4.83
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.95% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.60M USD | Price to earnings Ratio - | 1Y Target Price 4.83 |
Price to earnings Ratio - | 1Y Target Price 4.83 | ||
Volume (30-day avg) 1 | Beta 0.51 | 52 Weeks Range 1.50 - 2.87 | Updated Date 06/30/2025 |
52 Weeks Range 1.50 - 2.87 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -112.4% | Operating Margin (TTM) -63.56% |
Management Effectiveness
Return on Assets (TTM) -22.36% | Return on Equity (TTM) -52.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1782606 | Price to Sales(TTM) 1.62 |
Enterprise Value 1782606 | Price to Sales(TTM) 1.62 | ||
Enterprise Value to Revenue 0.42 | Enterprise Value to EBITDA 0.77 | Shares Outstanding 5728640 | Shares Floating 226359021 |
Shares Outstanding 5728640 | Shares Floating 226359021 | ||
Percent Insiders - | Percent Institutions 0.1 |
Analyst Ratings
Rating 1 | Target Price 4.83 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Immuron Ltd ADR
Company Overview
History and Background
Immuron Ltd ADR (IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered polyclonal antibodies for gut health. Founded in 1998, Immuron initially focused on infectious diseases before shifting to gut health and inflammation.
Core Business Areas
- Travelan: Travelan is Immuron's primary product, an over-the-counter (OTC) medicine designed to reduce the risk of travelers' diarrhea.
- Protectyn: Protectyn is a dietary supplement designed to target leaky gut.
- Research and Development: Immuron dedicates resources to research and development of new antibody-based therapies for various gut-related conditions.
Leadership and Structure
Immuron's leadership includes a CEO, CFO, and a board of directors. The company has a scientific advisory board that assists with research and development efforts.
Top Products and Market Share
Key Offerings
- Travelan: Travelan is an oral immunotherapy designed to prevent travelers' diarrhea. Market share data is difficult to ascertain exactly, but Travelan holds a substantial share of the preventative travelersu2019 diarrhea market. Competitors include preventative antibiotics (generally discouraged) and bismuth subsalicylate (Pepto-Bismol). Recent revenue from the product makes up the majority of Immuron's income.
- Protectyn: Protectyn is a dietary supplement designed to help with leaky gut by addressing inflammation. The market share data is minimal. Key competitors include companies providing supplements for gut health such as NOW Foods, Thorne Research and Garden of Life.
Market Dynamics
Industry Overview
The market for gut health products is growing, driven by increasing awareness of the importance of the gut microbiome and its impact on overall health. The market includes therapeutics, supplements, and diagnostic tools.
Positioning
Immuron is positioned as a specialist in orally delivered polyclonal antibody therapies for gut health. Its competitive advantage lies in its proprietary technology platform and its focus on developing targeted therapies.
Total Addressable Market (TAM)
The global gut health market is projected to reach billions of dollars. Immuron is positioned to capture a portion of this TAM through the sales of its current products and development of new therapies for gut-related conditions.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Established product (Travelan)
- Focus on a growing market
- Experienced leadership
Weaknesses
- Limited product portfolio
- Reliance on a single major product
- Small market capitalization
- History of financial losses
Opportunities
- Expansion into new markets
- Development of new therapies
- Partnerships with larger pharmaceutical companies
- Increased consumer awareness of gut health
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- ABT
- BMY
- MRK
Competitive Landscape
Immuron faces intense competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its specialized focus on gut health and its proprietary technology. Immuron is a very small player in the wider pharmaceutical marketplace dominated by much larger entities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, driven primarily by Travelan sales.
Future Projections: Future growth is dependent on the successful commercialization of new products and expansion into new markets. Analyst estimates vary widely, reflecting the uncertainty of the biopharmaceutical industry.
Recent Initiatives: Recent initiatives include expanding distribution partnerships for Travelan and developing new formulations of Protectyn.
Summary
Immuron is a small biopharmaceutical company focused on gut health with a primary product in Travelan. Its financial performance has been inconsistent, and the company relies heavily on fundraising. Expansion into new markets and the successful commercialization of new products are crucial for future growth. The company faces significant competition from larger pharmaceutical companies. Immuron also lacks strong market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Market research reports
- Company Press Releases
- Third Party Financial Analysis Sites
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immuron Ltd ADR
Exchange NASDAQ | Headquaters Carlton, VIC, Australia | ||
IPO Launch date 2017-06-09 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.immuron.com.au |
Full time employees 7 | Website https://www.immuron.com.au | ||
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.